Almeroth v. Innovative Clinical Solutions, Ltd. (In Re Innovative Clinical Solutions, Ltd.)

302 B.R. 136, 51 Collier Bankr. Cas. 2d 254, 2003 Bankr. LEXIS 1453, 42 Bankr. Ct. Dec. (CRR) 52, 2003 WL 22533881
CourtUnited States Bankruptcy Court, D. Delaware
DecidedNovember 7, 2003
Docket19-10461
StatusPublished
Cited by20 cases

This text of 302 B.R. 136 (Almeroth v. Innovative Clinical Solutions, Ltd. (In Re Innovative Clinical Solutions, Ltd.)) is published on Counsel Stack Legal Research, covering United States Bankruptcy Court, D. Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Almeroth v. Innovative Clinical Solutions, Ltd. (In Re Innovative Clinical Solutions, Ltd.), 302 B.R. 136, 51 Collier Bankr. Cas. 2d 254, 2003 Bankr. LEXIS 1453, 42 Bankr. Ct. Dec. (CRR) 52, 2003 WL 22533881 (Del. 2003).

Opinion

MEMORANDUM OPINION

PETER J. WALSH, Bankruptcy Judge.

This is with respect to Defendant Innovative Clinical Solutions, Ltd.’s (“ICSL”) motion (Doc. #77) to dismiss Plaintiffs’ second amended complaint in the above captioned adversary proceeding. 1 The second amended complaint consists of 15 separate counts embodied in 179 numbered paragraphs spanning 65 pages. As I indicated in my July 17, 2003 letter to counsel, this matter involves a rather complex factual scenario and disputed issues of law. Given the constraints on the Court’s time, it is not possible at this time to address the many issues raised by the non-debtor defendants motions to dismiss. However, I have devoted sufficient time to the matter now to conclude that relief in the form of a revocation order pursuant to 11 U.S.C. § 1144 is not appropriate. 2 Consequently, I will grant ICSL’s motion to the extent of dismissing those counts of the second amended complaint which are based on § 1144.

BACKGROUND

By its Chapter 11 petition, ICSL sought relief under Chapter 11 of the Bankruptcy Code through a prepackaged plan of reorganization (the “Plan”), the primary purpose of which was to exchange its $100 million of 6 3/4% Convertible Debentures (the “Debentures”) for newly issued Common Stock in ICSL.

Following negotiations with a steering committee consisting of holders of a majority (in amount) of the Debentures, on June 12, 2000, ICSL’s disclosure statement was distributed to all Debenture holders. The deadline for voting on the Plan was set at July 12, 2000. As of that date, 308 Debenture holders, representing an aggregate amount of the bonds of $74,453,000, remitted ballots on the Plan to ICSL’s voting agent. Of the 308 total bondholders, 193, or 62.7%, voted in favor of the Plan, representing an aggregate amount of the bonds of $68,870,000 or 92.5% of the total held by Debenture holders voting on the Plan.

Following the voting deadline, on July 14, 2000 ICSL and all of its existing subsidiaries filed voluntary petitions for relief *139 under Chapter 11. This Court set the hearing on the adequacy of the disclosure statement, the approval of the solicitation procedures, and confirmation of the Plan for August 23, 2000, and set August 14, 2000 as the deadline for filing any written objection thereto. None of Plaintiffs filed an objection and none of Plaintiffs filed an appearance in the Chapter 11 cases prior to confirmation of the Plan. In addition, none of Plaintiffs requested or conducted any discovery in these cases prior to confirmation.

At Plaintiff Steven L. Gidumal’s (“Gidu-mal”) request, the U.S. Trustee formed an official committee of unsecured creditors (“the Committee”) on August 17, 2000, six days before the confirmation hearing. The Committee consisted of six members, including Gidumal as the representative of Plaintiff Bond Opportunity Fund II, LLC (“BOF”). The Committee did not include any member of the pre-petition steering committee. Four of the six Committee members voted to support the Plan, with one abstention by the indenture trustee for the Debentures, and a lone vote against, by BOF through Gidumal. Based on the majority vote in favor of the Plan, the Committee filed a statement of the Committee in support of confirmation of the Plan.

This Court held the confirmation hearing on August 23, 2000, allowing objectors the opportunity to address the Court, and examine witnesses, regardless of whether they had complied with the scheduling order’s requirements regarding the filing of written objections to the Plan. Although none of Plaintiffs had filed an objection to the Plan, the Court allowed Gidumal, in his capacity as president of the BOF, to examine witnesses and present his objections orally. Gidumal did not raise any objections to the adequacy of the disclosure statement or the confirmability of the Plan under § 1129, including any of the objections raised in the second amended complaint. Instead, after cross-examining the Debtors’ witnesses, Gidumal merely asked the Court to modify the Plan by placing certain incentive bonuses due ICSL executives in escrow until the end of the fiscal year, at which time the bonuses would be paid out only if the company fully achieved the Plan projections. This Court denied Gidumal’s request, because he asked for unauthorized modifications to the Plan, without raising any objections to the adequacy of ICSL’s solicitation procedures, the adequacy of the disclosure statement, or the confirmation of the Plan. On August 25, 2000 the Court confirmed the Plan and on September 21, 2000 the Plan became effective (the “Effective Date”). The only class of claims impaired under the Plan was the class consisting of the Debenture holders.

On February 20, 2001 Plaintiffs filed their complaint seeking revocation of the confirmation order and other related relief. On March 29, 2001 Plaintiffs filed an amended complaint and on August 12, 2002 Plaintiffs filed their second amended complaint (the “Complaint”). Prior to having their Debentures converted into Common Stock, Plaintiffs owned an aggregated of $1,152,000 face amount of the Debentures, representing just over 1% of the $100 million of Debentures. No other former Debenture holders have sought relief from the confirmation order. The Complaint alleges, and Defendants do not dispute, that whereas the disclosure statement estimated the value of the new Common Stock to be in the range of $65 million to $95 million, ten months after the Effective Date the Common Stock was trading at $0.26 per share, giving ICSL a market capitalization of approximately $3 million. Presumably, there has been no improvement to date in the market value of the Common Stock. The Complaint alleges *140 that the effect of the Plan was to thwart Plaintiffs from realizing the true value of their Debenture holdings. Specifically, the Complaint alleges fraudulent conduct by Defendants for their failure to disclose alleged conflicts of interest, business relationships and other alleged vote procurement misconduct that enabled Defendants to achieve approval of the Plan to promote the personal interests of Defendants. 3

STANDARD OF REVIEW

In deciding a motion to dismiss a complaint filed under Fed.R.Civ.P. 12(b)(6), the court is required to determine whether, under any reasonable reading of the pleadings, plaintiffs may be entitled to relief, and must accept as true the factual allegations in the complaint and all reasonable inferences that can be drawn therefrom. Langford v. City of Atlantic City, 235 F.3d 845, 847 (3d Cir.2000). In considering a Rule 12(b)(6) motion, the court should not inquire whether the plaintiffs will ultimately prevail, only whether they are entitled to offer evidence in support of their claims. Scheuer v. Rhodes, 416 U.S. 232, 236, 94 S.Ct. 1683, 40 L.Ed.2d 90 (1974).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
302 B.R. 136, 51 Collier Bankr. Cas. 2d 254, 2003 Bankr. LEXIS 1453, 42 Bankr. Ct. Dec. (CRR) 52, 2003 WL 22533881, Counsel Stack Legal Research, https://law.counselstack.com/opinion/almeroth-v-innovative-clinical-solutions-ltd-in-re-innovative-clinical-deb-2003.